Taken together, these findings support that the DLBCL-derived CCDC50 + exosome could be a promising non-invasive biomarker for predicting patient outcomes and distinguishing between different subtypes of DLBCL. The gene discussed is CCDC50; the disease is diffuse large B-cell lymphoma.